| [1] |
马茜,侯萌,杨筱凤. 西安交通大学第一附属医院8581名妇女生殖道人乳头瘤病毒感染筛查[J]. 中国医学科学院学报,2014,36(3):277-282.
|
| [2] |
张倩,曹頔,马茜,等. 760名女性生殖道高危型人乳头瘤病毒感染自然转归规律及影响因素[J]. 中国医学科学院学报,2015,37(5):534-540.
|
| [3] |
Sakaguchi S,Yamaguchi T,Nomura T,et al.Regulatory T cells and immune tolerance[J]. Cell,2008,133(5):775-787.
|
| [4] |
Kim M,Grimmig T,Grimm M,et al.Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer[J]. PLoS One,2013,8(1):e53630.doi:10.1371/journal.pone. 0053630.
|
| [5] |
Hinz S,Pagerols-Raluy L,Oberg HH,et al.Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer[J]. Cancer Res,2007,67(17):8344-8350.
|
| [6] |
Wang WH,Jiang CL,Yan W,et al.FOXP3 expression and clinical characteristics of hepatocellular carcinoma[J]. World J Gastroenterol,2010,16(43):5502-5509.
|
| [7] |
Winerdal ME,Marits P,Winerdal M,et al.FOXP3 and survival in urinary bladder cancer[J]. BJU Int,2011,108(10):1672-1678.
|
| [8] |
Merlo A,Casalini P,Carcangiu ML,et al.FOXP3 expression and overall survival in breast cancer[J]. J Clin Oncol,2009,27(11):1746-1752.
|
| [9] |
Ladoire S,Arnould L,Mignot G,et al.Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat,2011,125(1):65-72.
|
| [10] |
Ebert LM,Tan BS,Browning J,et al.The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells[J]. Cancer Res,2008,68(8):3001-3009.
|
| [11] |
Belladonna ML,Orabona C,Grohmann U,et al.TGF-beta and kynurenines as the key to infectious tolerance[J]. Trends Mol Med,2009,15(2):41-49.
|
| [12] |
Freeman GJ,Long AJ,Iwai Y,et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. J Exp Med,2000,192(7):1027-1034.
|
| [13] |
Tseng SY,Otsuji M,Gorski K,et al.B7-DC,a new dendritic cell molecule with potent costimulatory properties for T cells[J]. J Exp Med,2001,193(7):839-846.
|
| [14] |
Latchman Y,Wood CR,Chernova T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol,2001,2(3):261-268.
|
| [15] |
Greenwald RJ,Freeman GJ,Sharpe AH.The B7 family revisited[J]. Annu Rev Immunol,2005,23(1):515-548.
|
| [16] |
Merelli B,Massi D,Cattaneo L,et al.Targeting the PD1/PD-L1 axis in melanoma:biological rationale,clinical challenges and opportunities[J]. Crit Rev Oncol Hematol,2014,89(1):140-165.
|
Acta Academiae Medicinae Sinica
)
